---
title: "DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286310007.md"
datetime: "2026-05-13T20:10:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286310007.md)
  - [en](https://longbridge.com/en/news/286310007.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286310007.md)
---

# DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.48.

EBIT: As of FY2026 Q1, the actual value is USD -2.005 M.

#### Cash and Cash Equivalents

As of March 31, 2026, cash and cash equivalents were $6,945 thousand, a decrease from $7,522 thousand as of December 31, 2025. The $600 thousand decrease during the first quarter of 2026 was attributed to $2,500 thousand of cash used in operations, partially offset by $2,000 thousand in net proceeds from ATM financing and a $100 thousand decrease from equity financing-related expenses.

#### Operating Costs

-   **Research and Development (R&D) Expenses**: For the quarter ended March 31, 2026, R&D expenses were $384 thousand, representing a decrease of $900 thousand compared to $1,281 thousand for the same period in 2025. This reduction was primarily due to a $700 thousand decrease in clinical expenses, a $100 thousand decrease in chemistry, manufacturing, and controls (CMC) and non-clinical expenses, and a $100 thousand decrease in personnel expenses.
-   **Selling, General and Administrative (SG&A) Expenses**: SG&A expenses increased to $1,542 thousand for the quarter ended March 31, 2026, from $1,058 thousand for the quarter ended March 31, 2025. This increase was mainly driven by $200 thousand in marketing expenses, $200 thousand in increased audit fees, and $100 thousand in increased legal fees.
-   **Total Operating Expenses**: Total operating expenses for the first quarter of 2026 were $1,926 thousand, down from $2,339 thousand for the same period in 2025.

#### Profitability

-   **Loss from Operations**: The loss from operations for the quarter ended March 31, 2026, was - $1,926 thousand, an improvement from - $2,339 thousand for the prior year’s comparable quarter.
-   **Interest Income**: Interest income increased to $79 thousand for the first quarter of 2026, compared to $36 thousand for the same period in 2025.
-   **Net Loss**: The net loss for the quarter ended March 31, 2026, was - $1,847 thousand, an improvement from - $2,303 thousand for the quarter ended March 31, 2025.

#### Unique Metrics

-   **Net Proceeds from ATM Financing**: Dermata Therapeutics, Inc. raised $2,000 thousand in net proceeds from its at-the-market (ATM) financing facility during the first quarter of 2026.

#### Outlook / Guidance

The company anticipates launching its first direct-to-consumer (DTC) product, the Tome Foundational Treatment, in the middle of 2026, with a second DTC product expected to follow. Current cash resources are projected to be sufficient to fund operations into the first quarter of 2027.

### Related Stocks

- [DRMAW.US](https://longbridge.com/en/quote/DRMAW.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Autohome Inc. to Announce First Quarter 2026 Financial Results on May 28, 2026 | ATHM Stock News](https://longbridge.com/en/news/286390966.md)
- [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)
- [Royce Small-Cap Trust (NYSE: RVT) as of Apr 30, 2026 | RVT Stock News](https://longbridge.com/en/news/287103750.md)